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Abstract
Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous group of cancers, and molecular subtyping
is necessary to better identify molecular-based therapies. While some classifiers have been established, no one has
integrated the expression profiles of long noncoding RNAs (lncRNAs) into such subtyping criterions. Considering the
emerging important role of lncRNAs in cellular processes, a novel classification integrating transcriptome profiles of both
messenger RNA (mRNA) and lncRNA would help us better understand the heterogeneity of TNBC.
Methods: Using human transcriptome microarrays, we analyzed the transcriptome profiles of 165 TNBC samples. We
used k-means clustering and empirical cumulative distribution function to determine optimal number of TNBC subtypes.
Gene Ontology (GO) and pathway analyses were applied to determine the main function of the subtype-specific genes
and pathways. We conducted co-expression network analyses to identify interactions between mRNAs and lncRNAs.
Results: All of the 165 TNBC tumors were classified into four distinct clusters, including an immunomodulatory subtype
(IM), a luminal androgen receptor subtype (LAR), a mesenchymal-like subtype (MES) and a basal-like and immune
suppressed (BLIS) subtype. The IM subtype had high expressions of immune cell signaling and cytokine signaling genes.
The LAR subtype was characterized by androgen receptor signaling. The MES subtype was enriched with growth factor
signaling pathways. The BLIS subtype was characterized by down-regulation of immune response genes, activation of cell
cycle, and DNA repair. Patients in this subtype experienced worse recurrence-free survival than others (log rank test,
P = 0.045). Subtype-specific lncRNAs were identified, and their possible biological functions were predicted using
co-expression network analyses.
Conclusions: We developed a novel TNBC classification system integrating the expression profiles of both mRNAs and
lncRNAs and determined subtype-specific lncRNAs that are potential biomarkers and targets. If further validated in a larger
population, our novel classification system could facilitate patient counseling and individualize treatment of TNBC.
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Background
Contrary to their description in previous studies as being
useless transcripts, long noncoding RNAs (lncRNAs) are
emerging as important regulators in gene regulation and
other cellular processes [1–6]. Recent studies have proved
that lncRNAs are tightly correlated with disease processes,
including cancer [4, 7–10]. The roles of lncRNAs in breast
cancer have also been widely researched, and a number of
novel mechanisms have been proposed [1–3, 11]. As with
other cancers, lncRNAs are involved in several develop-
mental and tumorigenic processes of breast cancer. Liu
et al. [2] reported that the lncRNA NIKLA, can directly
interact with the functional domains of signaling proteins,
serving as a class of NF-κB modulators to suppress breast
cancer metastasis. Another lncRNA, BRCA4, was reported
to direct cooperative epigenetic regulation downstream of
chemokine signals, and its expression correlated with ad-
vanced breast cancer [12]. Gupta et al. [13] observed in-
creased expression of the lncRNA, HOTAIR. in primary
breast tumors and metastases, and HOTAIR expression
level in primary tumors was a powerful predictor of even-
tual metastasis and death. Considering the important role
of lncRNAs in breast cancer tumorigenesis and develop-
ment, the study of lncRNAs might aid in understanding
the nature of this malignant disease.
One of the most aggressive breast cancer subtypes is
triple-negative breast cancer (TNBC), which lacks estro-
gen receptor (ER) and progesterone receptor (PR) ex-
pression and human epidermal growth factor receptor 2
(HER2) amplification [14, 15]. TNBC represents ap-
proximately 10–20 % of all breast cancers and has a lar-
ger tumor size, higher grade, more positive lymph
nodes, and poorer prognosis than other subtypes of
breast cancer [16, 17]. Due to the heterogeneity of the
disease and the absence of well-defined molecular tar-
gets, treatment of TNBC remains a clinical challenge.
Differences were observed in the responses of patients
with TNBC to the same adjuvant chemotherapy. Thus,
further classifying this aggressive disease subtype and
treating patients accordingly is a top priority and would
greatly benefit patients.
Several former studies have achieved significant progresses
in classifying TNBC. By analyzing publically available expres-
sion data for messenger RNA (mRNA), Lehmann et al. [18]
advanced the knowledge of TNBC and classified TNBC into
six subtypes: 1) luminal androgen receptor positive (LAR); 2)
claudin-low-enriched mesenchymal (M); 3) mesenchymal
stem-like (MSL); 4) immune response (M); and two cell
cycle-disrupted basal subtypes, 5) basal-like-1 (BL1) and 6)
basal-like-2 (BL2). In the present study, we refer to this as
the Lehmann/Pietenpol classification. However, a subsequent
study using the Lehmann/Pietenpol classification could not
readily distinguish BL1 and BL2 tumors [19]. Moreover, with
recent developments in high-throughput (gene sequencing)
technology, our knowledge of breast cancer is ever expand-
ing, and a classification based merely on gene expression
levels may be insufficient (for prospective individualized can-
cer treatment). A new classification system based on the inte-
grated expression profiles of mRNAs and lncRNAs might
offer more comprehensive data and identify stable subtypes
and subtype-specific targets.
Collectively, we questioned the possibility and utility
of subtyping TNBCs using whole-transcriptome expres-
sion analysis. By integrating the expression profiles of
both mRNAs and lncRNAs, we successfully classified
165 TNBC tumors into four distinct subtypes, each
displaying unique gene expression and ontology. Fur-
thermore, we identified subtype-specific lncRNAs and
predicted their possible biological functions using co-
expression network analysis. Our novel classification sys-
tem could facilitate individualized treatment for patients
with TNBC if validated in other reliable cohorts.
Methods
Patient recruitment
The present prospective observational study was initi-
ated on 1 January 2011. Patients who were diagnosed
with malignant breast cancer and willing to participate
in the study were recruited. A total of 165 consecutive
patients treated in the Department of Breast Surgery at
Fudan University Shanghai Cancer Center (FUSCC)
from 1 January 2011 to 31 December 2012 were enrolled
according to the following inclusion criteria: 1) female
patients diagnosed with unilateral invasive ductal carcin-
oma with phenotype ER–, PR–, and HER2–; 2) patho-
logic examination of tumor specimens performed by the
Department of Pathology at FUSCC. The ER, PR and
HER2 status was reconfirmed by two experienced pa-
thologists (WTY and RHS) based on immunochemical
analysis and in situ hybridization [20]; 3) patients with-
out any evidence of metastasis at diagnosis; and 4) suffi-
cient frozen tissue for further research. Patients with
breast carcinoma in situ (with or without microinvasion)
and inflammatory breast cancer were excluded. Clinico-
pathological characteristics (including age, menopausal
status, tumor histologic type, tumor size, lymph node
status, histologic grade, ER, PR, HER2, Ki67, and adju-
vant therapies) and local and distant extent of disease
(evaluated by chest computed tomography (CT), bone
scan, abdominal ultrasound, bilateral mammography,
breast ultrasound or magnetic resonance imaging (MRI))
were collected [21].
Follow up of patients in the cohort was completed on
31 December 2014. The median length of follow up was
13.9 months (interquartile range, 8.6–21.1 months). Our
definition of recurrence-free survival (RFS) events in-
cluded: the first recurrence of invasive disease at a local,
regional, or distant site; the diagnosis of contralateral
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breast cancer; and death from any causes. Patients with-
out events were censored at the last follow up.
All tissue samples included in this study were obtained
with approval of the independent ethical committee/in-
stitutional review board at Fudan University Shanghai
Cancer Center Ethical Committee, and each patient
signed an informed consent form.
Sample preparation and microarray experiment
Tumor tissues were macro-dissected to avoid the influ-
ence of stromal tissues (<10 %). The percentage of
tumor cells was confirmed to be 90 % or more in all
breast cancer specimens. Total RNA was isolated from
165 frozen TNBC samples using the Rneasy Plus Mini
Kit (Qiagen, Valencia, CA, USA). The purity and quantity
of total RNA were estimated by measuring absorbance at
260 nm (A260) and 280 nm (A280) with RNase-free water
as a blank control, using a NanoDrop 2000 spectropho-
tometer (Thermo Scientific, Wilmington, DE, USA). Only
when the ratio of A260/A280 was within 1.9–2.1, were the
extracted RNAs deemed as pure and suitable for future
experimentation. Microarray analysis was performed using
the Affymetrix Human Transcriptome Array 2.0 (HTA
2.0) GeneChips (Affymetrix, Santa Clara, CA, USA) as
previously described [22].
The mRNA-lncRNA-based TNBC subtyping and the
Lehmann/Pietenpol classification
We performed k-means clustering and consensus clustering
to determine the optimal number of stable TNBC subtypes.
Cluster robustness was assessed by consensus clustering
using agglomerative k-means clustering (1,000 iterations),
with average linkage on the 165 TNBC profiles using the
2,535 most differentially expressed genes (SD >0.65) (Gene
Pattern version 3.2.1, http://www.broadinstitute.org/cancer/
software/genepattern/). The optimal number of clusters
was determined from the empirical cumulative distribution
function (CDF), which plots the corresponding empirical
cumulative distribution, defined over the range, and from
calculation of the proportion increase in the area under the
CDF curve [18]. In addition, we considered the number of
patients in each subtype. If there were fewer than five
patients in one subtype, we deemed the classification as un-
stable. Thus, the optimum number of clusters moved to
the minor number.
The Lehmann/Pietenpol classification system was
established by analyzing 587 TNBC gene expression pro-
files from 21 publicly available datasets [18]. The authors
have developed a web-based subtyping tool for classify-
ing TNBC samples based on their collected gene expres-
sion meta-data [23]. Using this web-based algorithm [23]
(http://cbc.mc.vanderbilt.edu/tnbc/), we obtained sub-
types of our samples in the Lehmann/Pietenpol classifi-
cation system. Spearman’s correlation analysis was used
to assess the relationship between the Lehmann/Pietenpol
classification system and our novel system.
Gene Ontology (GO) and pathway analysis
GO analysis was applied to analyze the main function of
the subtype-specific genes according to the GO database,
which is the key functional classification of the National
Center for Biotechnology Information (NCBI). The ana-
lysis can organize genes into hierarchical categories and
uncover the gene regulatory network based on biological
process and molecular function [24–26]. Meanwhile,
pathway analysis was used to determine the significant
pathways of the differential genes according to the Kyoto
Encyclopedia of Genes and Genomes database (KEGG)
[27]. The Pearson chi-square test and Fisher’s exact test
were used to select the significant pathway.
Co-expression network analysis
To identify interactions between mRNAs and lncRNAs,
we constructed co-expression networks [28]. We pre-
processed the data using the median expression value of
all transcripts and then screened for differentially
expressed lncRNAs and mRNAs among subtypes. For
each pair of genes analyzed, we calculated the Pearson
correlation and chose pairs (only lncRNA-mRNA) with
significant correlation in order to construct the network
(P <0.05). To make a visual representation, only those
with the strongest correlation (correlation coefficient ≥0.95)
were included in the renderings. The co-expression
networks were drawn using Cytoscape 2.8.2 [29],
which is open-source software for integration, analysis
and visualization of biological networks.
Statistical analysis
All analyses were performed according to the reporting
recommendations for tumor marker prognostic studies
(REMARK) for prognostic and tumor marker studies, and
the respective guidelines of microarray-based studies for
clinical outcomes. Frequency tabulation and summary
statistics were used to characterize the data distribution.
Student’s t test was utilized to compare continuous vari-
ables, and the Pearson chi-square test was employed for
the comparison of categorical variables. Survival curves
were constructed using the Kaplan–Meier method and
compared between subtypes with the log rank test. Sur-
vival analyses were performed using SPSS 20.0 (SPSS Inc.,
Chicago, IL, USA). All tests were two-sided, and P <0.05
was regarded as significant, unless otherwise stated.
Microarray data
Microarray data have been deposited into the Gene Ex-
pression Omnibus (GEO) database (http://www.ncbi.nlm.
nih.gov/geo/) [GEO:GSE76250].
Liu et al. Breast Cancer Research  (2016) 18:33 Page 3 of 10
Results
Transcriptome profiling of TNBC reveals four stable
molecular subtypes
According to the inclusion criteria, a total of 165 TNBC
samples qualified for the present study. To identify global
differences in transcriptome profiles in TNBC subtypes,
we performed k-means clustering on the most differen-
tially expressed mRNAs and lncRNAs (SD >0.65). All 165
TNBC tumors were classified into four stable clusters
(Figs. 1 and 2). The robustness of the classification was an-
alyzed by consensus clustering involving k-means cluster-
ing by resampling (1,000 iterations) randomly selected
tumor profiles (Fig. 1). Clinical and pathological character-
istics of patients with TNBC are presented according to
the four subtypes (Table 1).
To understand the nature of each subtype in our system,
GO and pathway analyses were performed to determine
the top GO and canonical pathways associated with
TNBC subtypes. Each subtype, presenting distinct regula-
tor activation and inhibition patterns, was characterized
based on the results. The results were correlated with the
distribution of the Lehmann/Pietenpol subtypes in our
new classification system, which we named the FUSCC
classification. Detailed GO and pathway analysis results of
each subtype are presented in Additional file 1: Table S1.
Cluster A: the immunomodulatory (IM) subtype
In concordance with the Lehmann/Pietenpol classification,
the IM subtype presented unique GOs and pathways in-
volving immune cell process. These processes included
cytokine signaling (cytokine-cytokine receptor interaction),
immune cell signaling (T-cell receptor signaling pathway,
B-cell receptor signaling pathway), antigen processing and
presentation, chemokine signaling pathway, and immune
signal transduction pathway (NF-κB signaling pathway).
The most upregulated gene functions were tightly con-
nected with immune functions, such as immune response,
T cell co-stimulation, and innate immune response. The
genes involved in the most significantly upregulated func-
tions are also involved in the immune response process
(CCR2, CXCL13, CXCL11, CD1C, CXCL10, and CCL5),
which further confirmed the major role of functions re-
lated to immunity in this subtype.
Cluster B: the luminal androgen receptor (LAR) subtype
The LAR type displayed unique GOs, which were highly
enriched in hormonally regulated pathways. Androgen
and estrogen metabolism, steroid hormone biosynthesis,
porphyrin and chlorophyll metabolism, and peroxisome
proliferator-activated receptor (PPAR) signaling path-
ways were significantly elevated in this subtype. Al-
though these tumors were confirmed to be TNBC by
immunohistochemical analysis, the gene expression pro-
filing demonstrated an upregulated estrogen signaling
pathway. These results suggested this subtype might re-
spond to anti-androgen and traditional anti-estrogen
therapies. Thus, to be consistent with previous studies,
we classified this as the LAR subtype [18, 30].
Cluster C: the mesenchymal-like (MES) subtype
This cluster displayed a variety of unique GOs and involved
pathways. Enriched pathways in this subtype included
extracellular matrix (ECM)-receptor interaction, focal adhe-
sion, and transforming growth factor (TGF)-beta signaling
pathway, and processes linked to growth factor signaling
pathways (ABC transporter and adipocytokine signaling
Fig. 1 The identification of novel subtypes of triple-negative breast cancer. a Consensus clustering displaying the robustness of classification.
b Consensus empirical cumulative distribution function (CDF) of all given cluster numbers. c Plot of delta area changes with number of clusters
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pathway). Moreover, the MES subtype had low levels of
genes related to cell proliferation. The decreased prolifera-
tion involved the process of cell division (CCNE2, PARD6B,
CDCA2, KIF2C, SKA1, NEK2, CDK1, CDC6), mitotic cell
cycle (NDC80, CENPW, MAD2L1, CENPI, CCNB1,
CENPF, CCNA2), mitotic prometaphase (MAD2L1,
NCAPG, SGOL1, KIF18A, PLK1), and mitosis (ASPM,
HELLS, KIF11, NUF2). The major subtype of the Lehmann/
Pietenpol classification in this cluster was MSL (Figs. 2
and 3). Altogether, we named this cluster the MES subtype.
Cluster D: the basal-like and immune-suppressed (BLIS)
subtype
For this subtype, the top GOs were enriched in cell div-
ision and cell cycle related pathways (mitotic cell cycle,
mitotic prometaphase, M phase of mitotic cell cycle, DNA
replication, and DNA repair). The enhanced expression of
genes associated with proliferation, such as CENPF, BUB1,
PRC1, further supported the highly proliferative nature of
this subtype. Meanwhile, genes involved in immune re-
sponses (immune response and innate immune response),
immune cell signaling pathways (T cell co-stimulation, T
cell receptor signaling pathway, B cell activation, and den-
dritic cell chemotaxis) and complement activation pro-
cesses were significantly downregulated. Previous survival
analysis indicated that patients in the BLIS subtype experi-
enced worse RFS compared to other patients. This finding
is in concordance with the highly proliferative and
immune-suppressed nature of these tumors.
Association between the FUSCC classification and the
Lehmann/Pietenpol classification system
In the Lehmann/Pietenpol classification system [18],
TNBCs were classified into seven subtypes (BL1, BL2,
Fig. 2 A heat map shows the relative expression of the top differentially expressed RNAs (SD >0.65) in each subtype. Top Gene Ontology (GO)
and canonical pathways of each subtype are shown (left). Upward-pointing arrow upregulated function, downward-pointing arrow downregulated
function. FUSCC Fudan University Shanghai Cancer Center, IM immunomodulatory, LAR luminal androgen receptor, MES mesenchymal-like, BLIS
basal-like and immune suppressed, BL basal-like, M claudin-low-enriched mesenchymal, MSL mesenchymal stem-like, ECM extracellular matrix,
TGF transforming growth factor
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LAR, M, IM, MSL, and UNS), whereas according to the
FUSCC system, TNBC tumors were divided into four stable
subtypes. We then investigated to what extent the FUSCC
subtypes based on integrated mRNA-lncRNA expression
were associated with the mRNA-based Lehmann/Pietenpol
classification (Fig. 2). In Spearman’s correlation analysis, we
found that the two classification systems were significantly
associated with each other (P = 0.039). Further analysis of
the distribution of the Lehmann/Pietenpol subtypes in the
FUSCC classification system revealed that our subtype IM
was nearly identical to the Lehmann/Pietenpol IM type;
our subtype LAR mainly contained the LAR type; our sub-
type MES included all six of the Lehmann/Pietenpol sub-
types, with the MSL and M subtypes accounting for the
Table 1 Clinicopathological characteristics of the four TNBC subtypes based on the FUSCC classification criteria
FUSCC subtypes
Characteristics Number IM LAR MES BLIS P
(total = 165) n = 28 n = 29 n = 55 n = 53
Age, y 0.024
≤50 68 14 (50.0) 6 (20.7) 20 (36.4) 28 (52.8)
>50 97 14 (50.0) 23 (79.3) 35 (63.6) 25 (47.2)
Menopause 0.160
Yes 101 16 (57.1) 23 (79.3) 33 (60.0) 29 (54.7)
No 64 12 (42.9) 6 (20.7) 22 (40.0) 24 (45.3)
Tunor size, cm 0.409
≤2 cm 58 14 (50.0) 12 (41.4) 15 (27.3) 17 (32.1)
>2 cm 104 13 (46.4) 17 (58.6) 39 (70.9) 35 (66.0)
Unknown 3 1 (3.6) 0 (0.0) 1 (1.8) 1 (1.9)
Tumor grade 0.311
≤ II 32 4 (14.3) 9 (31.0) 13 (23.6) 6 (11.3)
> II 104 17 (60.7) 17 (58.6) 33 (60.0) 37 (69.8)
Unknown 29 7 (25.0) 3 (10.3) 9 (16.4) 10 (18.9)
Ki67, % 0.286
<14 8 0 (0.0) 0 (0.0) 3 (5.5) 5 (9.4)
≥14 156 28 (100.0) 29 (100.0) 51 (92.7) 48 (90.6)
Unknown 1 0 (0.0) 0 (0.0) 1 (1.8) 0 (0.0)
Positive lymph nodes 0.019
0 86 8 (28.6) 13 (44.8) 28 (50.9) 37 (69.8)
1-3 29 6 (21.4) 5 (17.2) 10 (18.2) 8 (15.1)
> 3 50 14 (50.0) 11 (37.9) 17 (30.9) 8 (15.1)
Chemotherapy 0.642
Taxane-based 124 21 (75.0) 22 (75.9) 42 (76.4) 39 (73.6)
Non-taxane-based 27 5 (17.9) 3 (10.3) 11 (20.0) 8 (15.1)
Unknown 14 2 (7.1) 4 (13.8) 2 (3.6) 6 (11.3)
Radiotherapy 0.038
Yes 50 16 (57.1) 9 (31.0) 14 (25.5) 11 (20.8)
No 103 11 (39.3) 20 (69.0) 37 (67.3) 35 (66.0)
Unknown 12 1 (3.6) 0 (0.0) 4 (7.3) 6 (11.3)
Follow up, month
Median 13.9 14.7 12.4 14.3 12.6
IQR 8.6–21.1 10.0–22.4 8.6–19.0 10.6–21.5 8.0–18.4
RFS events 22 5 4 4 9
BLIS basal-like and immune suppressed, FUSCC Fudan University Shanghai Cancer Center, IM immunomodulatory, IQR interquartile range, LAR luminal androgen
receptor, MES mesenchymal-like, RFS recurrence-free survival
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majority; and our subtype BLIS mainly contained the
Lehmann/Pietenpol BL1 and M types (Fig. 3).
Survival analysis of patients in the four subtypes
We conducted survival analysis to explore correla-
tions between the four subtypes and RFS. Kaplan–
Meier survival analysis showed that there was no
significant difference in RFS between the four sub-
types (Fig. 4a). However, when we analyzed the data
by comparing one subtype with the others, we found
that patients in the subtype BLIS experienced worse
RFS than the remaining patients with TNBC (Fig. 4b,
log rank P = 0.045).
Identifying subtype-specific lncRNAs and their co-expressed
mRNAs
We identified differentially expressed lncRNAs in each sub-
type by comparing the expression intensity of lncRNAs in
one specific subtype with the others. Differentially upregu-
lated lncRNAs are as shown in Fig. 5. In the IM subtype,
the most upregulated lncRNA was ENST00000443397,
which was tightly correlated with five mRNAs (Fig. 5a).
LncRNA ENST00000447908 was highly expressed in the
LAR subtype, and ten mRNAs were significantly associated
with it (Fig. 5b). In the MES subtype, expression of lncRNA
NR_003221 was increased, and it was positively related with
two mRNAs and negatively associated with one mRNA
(Fig. 5c). LncRNA TCONS_00000027 was also a novel
Fig. 3 Interaction analysis of the Lehmann/Pietenpol and Fudan University Shanghai Cancer Center (FUSCC) classifications. X-axis shows the
subtypes of the new system. Circle size varies in proportion to the number of samples. MSL mesenchymal stem-like, LAR luminal androgen receptor,
M claudin-low-enriched mesenchymal, IM immunomodulatory, BL basal-like, MES mesenchymal-like, BLIS basal-like and immune-suppressed
Fig. 4 Kaplan-Meier plot and logrank test compared recurrence-free survival (RFS) in different subtypes according to the Fudan University Shanghai
Cancer Center (FUSCC) classification. a Difference in RFS among four subtypes. b RFS in patients with the basal-like 1 (BL1) subtype compared to other
subtypes. IM immunomodulatory, LAR luminal androgen receptor, MES mesenchymal-like, BLIS basal-like and immune-suppressed
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lncRNA that was highly expressed in the BLIS sub-
type; nine mRNAs were significantly correlated with
it (Fig. 5d). For these four lncRNAs, we further vali-
dated their subtype-specific expression in a cohort of
breast cancer cell lines and TNBC samples using quantita-
tive real-time PCR (Additional file 2: Figure S5, S6).
On further in situ hybridization, we validated that
lncRNAs TCONS_00000027 were highly expressed in
TNBC samples (Additional file 2: Figure S7). Several
other subtype-specific lncRNAs and their basic infor-
mation are listed in Additional file 2: Figures S1-S4.
Discussion
In the present study, we established a novel TNBC classifi-
cation system, the FUSCC classification, by integrating the
expression profiles of both mRNAs and lncRNAs. TNBC
samples can be clearly classified into four subtypes
according to our system: IM, LAR, MES, and BLIS. Each
subtype has its own unique transcriptome profile. Further-
more, we filtrated out several subtype-specific lncRNAs
and predicted possible functions of these lncRNAs in
TNBC biological processes by analyzing the co-expression
network between lncRNAs and mRNAs. To the best of
our knowledge, the present study is the first to develop a
novel TNBC classification system based on the transcrip-
tome profiles of both mRNAs and lncRNAs in a large
TNBC cohort.
Several novel findings were revealed in our in-depth
transcriptome analysis. First, considering the expanding
roles of lncRNAs in tumorigenesis and disease develop-
ment, we integrated the expression profiles of both
mRNAs and lncRNAs in an attempt to comprehensively
understand the heterogeneic nature of TNBC. By clus-
tering TNBC samples into four unique subtypes, the
Fig. 5 Subtype-specific long noncoding RNAs (lncRNAs) and analysis of their co-expressed messenger RNAs (RNAs). Table shows details of the
lncRNAs. The highest expression group was selected as the reference. Student’s t test, ***P <0.001. IM immunomodulatory, LAR luminal androgen
receptor, MES mesenchymal-like, BLIS basal-like and immune-suppressed, MSL mesenchymal stem-like
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FUSCC classification is more simplified than the former
Lehmann/Pietenpol system, but we could also recognize
some overlaps between the two systems. In the Lehmann/
Pietenpol classification, TNBC patients were assigned to
six different subtypes according to the combined analysis
of 14 publically available RNA profiling datasets [18].
However, subsequent study using the Lehmann/Pietenpol
system did not readily distinguish BL1 and BL2 tumors
[19]. In our present study, tumors with a basal property
were classified into only one subtype (BLIS) that incorpo-
rated almost all of the BL1 and BL2 subtypes from the
Lehmann/Pietenpol classification. The BLIS subtype is
associated with genes involved in proliferation and im-
munosuppression. Moreover, in the survival analysis, we
observed a worse survival outcome for this subtype com-
pared with other subtypes. The results are concordant
with those of a previous study in which patients with the
same property (basal-like immune-suppressed) had the
worst outcome among patients with TNBC [30]. Further-
more, almost all of the BLIS tumors were in the group at
high risk of relapse according to the TNBC prognostic sig-
nature that we developed (unpublished data). Collectively,
these results suggest the aggressive nature of BLIS tumors.
Thus, if these results are further validated in other larger
populations or prospective cohorts, more aggressive treat-
ment should be tailored for this group of patients.
In the study of Reiche [11], differentially expressed
lncRNAs were identified with relation to cancer-related
protein-coding genes. This suggests a tight connection
between lncRNA and mRNA. Through bioinformatics
analyses, we identified several subtype-specific lncRNAs
that will be functionally investigated in the future. By
analyzing co-expression networks, mRNAs that are
highly correlated with the subtype-specific lncRNAs
were identified. For example, lncRNA NR_003221 in the
MES subtype is positively correlated with mRNA CNN1
and SELP, but negatively correlated with mRNA ADH1B.
SELP encodes selectin P, which could mediate the inter-
actions between endothelial cells and leukocytes. A study
has shown that high selectin P expression is associated
with metastasis of small cell lung cancer [31]. Together
with chondroitin sulfate proteoglycan 4, selectin P can
bind to highly metastatic breast cancer cells and removal
of selectin P ligand could reduce metastatic lung
colonization [32]. ADH1B encodes alcohol dehydrogenase.
Decreased expression of ADH1B gene has been proved to
be associated with disease progression in human colorec-
tal cancer [33]. Taken together, we hypothesize that
lncRNA NR_003221 may play a role in cancer develop-
ment by promoting cell metastasis.
Our study has several limitations. First, the new classi-
fication has not yet been validated in other cohorts. Due
to the limited data on lncRNA expression in TNBC, we
did not validate the system in publicly available datasets.
Second, even though GO and pathway analyses were per-
formed, the nature of each subtype was not thoroughly
clarified, and in particular, lacked support from functional
experiments. Third, the follow-up time of the prospective
observational study was relatively short, and may have re-
sulted in the marginal difference in survival (BLIS vs.
others). Further updating the follow-up data might help
clarify the association between subtypes and survival out-
come. Last, compared with other available technology,
such as RNAseq, the HTA2.0 cannot identify novel
lncRNAs. Therefore, our future work will focus on updat-
ing the follow up of the cohort, recruiting independent co-
horts to validate the FUSCC classifier and investigating
the functions of novel lncRNAs in each subtype.
Conclusions
We have developed a novel TNBC subtyping system,
assigning TNBC patients to four distinct subtypes by in-
tegrating both mRNA and lncRNA expression profiles.
In addition, we revealed a number of novel subtype-
specific lncRNAs that help elucidate the nature of each
subtype. Once further validated in a larger population,
the subtype system could facilitate individualized treat-
ment of TNBC.
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Additional file 1: Top gene ontologies and pathways involved in each
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